Trial Profile
A Phase I, adaptive, open-label, single ascending dose to single-blind, placebo-controlled, multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of mRNA-0184 in participants with chronic heart failure
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Mar 2024
Price :
$35
*
At a glance
- Drugs MRNA-0184 (Primary)
- Indications Chronic heart failure
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca; Moderna Therapeutics
- 20 Nov 2023 Planned End Date changed from 7 May 2024 to 6 Mar 2025.
- 20 Nov 2023 Planned primary completion date changed from 7 May 2024 to 6 Mar 2025.
- 17 Aug 2023 Status changed from recruiting to active, no longer recruiting.